Published in BMC Nephrol on October 10, 2013
Alloantibody Generation and Effector Function Following Sensitization to Human Leukocyte Antigen. Front Immunol (2016) 0.79
Post-transplant blood transfusions and pediatric renal allograft outcomes. Pediatr Transplant (2016) 0.75
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Clin Drug Investig (2016) 0.75
Desensitization protocol enabling pediatric crossmatch-positive renal transplantation: successful HLA-antibody-incompatible renal transplantation of two highly sensitized children. Pediatr Nephrol (2016) 0.75
The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health (1998) 17.71
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet (2005) 2.02
Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation (2008) 1.82
Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int (2011) 1.53
Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation (2007) 1.50
Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant (2011) 1.48
Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation (2009) 1.47
Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome. Transplantation (1990) 1.43
Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant (2006) 1.38
Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol (2001) 1.26
Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation (1997) 1.15
Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation (2008) 1.13
Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation (1991) 1.12
Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant (2006) 1.09
Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol (2009) 1.09
Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol (2009) 1.08
Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol (2007) 1.08
Dominant effect of transfusions on kidney graft survival. Transplantation (1980) 1.07
Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant (2007) 1.05
Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant (2008) 1.03
How important is transfusion avoidance in 2013? Nephrol Dial Transplant (2013) 0.97
Dominant effect of histocompatibility on ten-year kidney transplant survival. Transplantation (1988) 0.95
Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation (2010) 0.95
Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation (2010) 0.95
Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation (2005) 0.92
Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol (2012) 0.92
Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation (2003) 0.92
The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients. Transplantation (1987) 0.90
Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation (2003) 0.89
Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Chin Med J (Engl) (2009) 0.89
Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2011) 0.88
Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol (2009) 0.86
The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant (1999) 0.84
The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant (2003) 0.84
Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation (1989) 0.82
A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation. Transpl Int (1994) 0.82
Effect of donor-specific transfusions on the outcome of renal allografts in the cyclosporine era. Transpl Int (2006) 0.81
Alloantibodies and outcomes of deceased donor kidney allografts. Hum Immunol (2009) 0.81
Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant (2010) 0.80
Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation (2001) 0.80
Comparison of two drug regimens upon clinical outcome among renal transplant recipients with positive flow cytometric crossmatches. Clin Transplant (2002) 0.80
Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch. Exp Clin Transplant (2009) 0.80
B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol (2002) 0.79
T-cell flow-cytometry crossmatch and long-term renal graft survival. Clin Transplant (2004) 0.79
The transfusion effect in cadaver kidney transplants--yes or no. Transplantation (1990) 0.79
Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: the North Italy Transplant program approach. Hum Immunol (2009) 0.78
Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant (2010) 0.78
Human leukocyte antigens DR and AB and kidney retransplantation. Transplantation (2003) 0.78
Causes of sensitisation in patients awaiting renal transplantation in Ireland. Ir Med J (2003) 0.78
The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation (1987) 0.77
Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation (2005) 0.77
Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int (2001) 0.77
Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation (2006) 0.77
Flow cytometric crossmatching and long-term kidney allograft survival in donor-specific transfusion patients. Transplantation (1991) 0.76
HLA-DRB1 compatibility in cadaver kidney transplantation: correlation with graft survival and function. Transpl Int (1995) 0.76
The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. Clin Transplant (1993) 0.76
Donor-specific antibodies by flow single antigen beads in pediatric living donor kidney transplants: single center experience. Pediatr Transplant (2007) 0.76
Immunology of renal transplantation in Singapore. Ann Acad Med Singapore (1988) 0.76
Renal graft survival is not influenced by a positive flow B-cell crossmatch. Clin Transplant (2007) 0.76
B cell positive cross-match not due to anti-HLA Class I antibodies and first kidney graft outcome. Transpl Immunol (2008) 0.76
Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients. Chin Med J (Engl) (2006) 0.76
Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - examination of 238 cases of renal transplantation. Transpl Int (2005) 0.76
Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients. Nephrol Dial Transplant (1992) 0.76
Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants. Clin Transplant (2009) 0.76
Promoter-region alleles of the TNF-alpha and IL-10 genes have no effect on pretransplant alloantibody production. Transplantation (2001) 0.76
The current role of pre-transplant blood transfusions and tissue typing in cadaveric renal transplantation. J Urol (1987) 0.76
Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. Transpl Int (1992) 0.76
Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00
Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity (2009) 3.32
TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant (2004) 3.15
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (2009) 2.87
Epigenetic mechanisms of regulation of Foxp3 expression. Blood (2009) 2.27
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause (2012) 2.21
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13
c-Maf regulates IL-10 expression during Th17 polarization. J Immunol (2009) 1.99
Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A (2009) 1.95
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis (2013) 1.79
Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience. Transplantation (2012) 1.79
Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol (2007) 1.71
Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol (2007) 1.64
Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol (2005) 1.64
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Dialysis practices that distinguish facilities with below- versus above-expected mortality. Clin J Am Soc Nephrol (2010) 1.50
Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes (2006) 1.49
Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48
Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol (2003) 1.45
Ablative fractionated CO2 laser treatment of photoaging: a clinical and histologic study. Dermatol Surg (2012) 1.45
Enhanced healing of surgical wounds of the lower leg using weekly zinc oxide compression dressings. Dermatol Surg (2011) 1.43
IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol (2005) 1.42
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant (2004) 1.39
Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis (2010) 1.36
Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Stat1 signals. Blood (2007) 1.29
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27
Committing embryonic stem cells to early endocrine pancreas in vitro. Stem Cells (2004) 1.23
FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest (2003) 1.18
T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol (2008) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation (2011) 1.15
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant (2003) 1.12
Regulatory T cell migration during an immune response. Trends Immunol (2012) 1.10
Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol (2009) 1.10
Adenovirus transduction induces expression of multiple chemokines and chemokine receptors in murine beta cells and pancreatic islets. Am J Transplant (2003) 1.08
The kinetics and pattern of tracheal allograft re-epithelialization. Am J Respir Cell Mol Biol (2003) 1.07
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2008) 1.06
Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol (2008) 1.06
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood (2009) 1.04
Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providers. Clin J Am Soc Nephrol (2008) 1.04
Laparoscopic donor nephrectomy: intraoperative safety, immediate morbidity, and delayed complications with 500 cases. Surg Endosc (2006) 1.02
Insulin-expressing colonies developed from murine embryonic stem cell-derived progenitors. Diabetes (2007) 1.01
The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol (2007) 1.01
Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation. J Am Soc Nephrol (2004) 1.01
Myeloid derived suppressor cells in transplantation. Curr Opin Immunol (2011) 0.99
Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation (2011) 0.99
Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant (2006) 0.99
Thalidomide for the treatment of refractory necrobiosis lipoidica. Arch Dermatol (2006) 0.99
Orthotopic tracheal transplantation in the murine model. Transplantation (2002) 0.98
FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol (2004) 0.98
L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol (2002) 0.97
Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant (2004) 0.97
Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant (2013) 0.96
Regulatory T cell induction, migration, and function in transplantation. J Immunol (2012) 0.96
Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol (2002) 0.96
Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS One (2011) 0.95
Islet expression of M3 uncovers a key role for chemokines in the development and recruitment of diabetogenic cells in NOD mice. Diabetes (2007) 0.95
The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nurs (2007) 0.94
Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. J Immunol (2005) 0.94
Functional specialization of islet dendritic cell subsets. J Immunol (2012) 0.92
Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ (2011) 0.92
Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int (2005) 0.92
Factors associated with improvement in deceased donor renal allograft function in the 1990s. J Am Soc Nephrol (2005) 0.91
Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 0.91
Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol (2004) 0.91
Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91
CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes (2006) 0.91
Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol (2002) 0.90
Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis (2008) 0.90
Orthotopic tracheal allografts undergo reepithelialization with recipient-derived epithelium. Arch Otolaryngol Head Neck Surg (2003) 0.90
Novel method of minimally invasive removal of large lipoma after laser lipolysis with 980 nm diode laser. Dermatol Ther (2011) 0.90
Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant (2013) 0.90
Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol (2013) 0.90
A functional role for CCR6 on proallergic T cells in the gastrointestinal tract. Gastroenterology (2009) 0.89
Long-term kidney regraft survival from deceased donors: risk factors and outcomes in a single center. Transplantation (2008) 0.88
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant (2011) 0.88
Therapeutic manipulation of T cell chemotaxis in transplantation. Curr Opin Immunol (2004) 0.88
Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance. Transplantation (2015) 0.88
Laminins affect T cell trafficking and allograft fate. J Clin Invest (2014) 0.88
Characterization of an in vitro differentiation assay for pancreatic-like cell development from murine embryonic stem cells: detailed gene expression analysis. Assay Drug Dev Technol (2011) 0.87
Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation (2008) 0.87
Photodynamic diagnosis of tumor margins using methyl aminolevulinate before Mohs micrographic surgery. J Am Acad Dermatol (2011) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
Differential chemokine and chemokine receptor gene induction by ischemia, alloantigen, and gene transfer in cardiac grafts. Am J Transplant (2003) 0.86
Leukotrienes, sphingolipids, and leukocyte trafficking. J Immunol (2003) 0.86
Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation (2005) 0.85
Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur J Immunol (2010) 0.85
Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation (2003) 0.85
Efficiency of U.S. dialysis centers: an updated examination of facility characteristics that influence production of dialysis treatments. Health Serv Res (2013) 0.84
Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol (2008) 0.84
Plasmacytoid dendritic cells in tolerance. Methods Mol Biol (2011) 0.84
Efficacy of hemodialysis and charcoal hemoperfusion in carbamazepine overdose. Clin Toxicol (Phila) (2008) 0.84
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int (2010) 0.83
Stat4 is critical for the balance between Th17 cells and regulatory T cells in colitis. J Immunol (2011) 0.83
Tolerance and lymphoid organ structure and function. Front Immunol (2011) 0.83
Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol (2005) 0.83
Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. Transplantation (2016) 0.83
Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation (2014) 0.83